News Carlyle backs Essential refinancing and other funding news Essential Pharma announces a €900m recapitalisation deal, while Noema Pharma, Angitia Biopharma, Citryll, and Veradermics also raise new cash.
News Essential adds neuroblastoma drug with Renaissance buy Essential Pharma has bought fellow UK drugmaker Renaissance Pharma, adding its first development-stage drug candidate, a therapy for hard-to-treat rare cancer neuroblastom
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.